Recent Blog Articles
Late-stage cervical cancer on the rise: What to know
A mindful way to help manage type 2 diabetes?
Close relationships with neighbors influence cardiovascular health in Black adults
Why play? Early games build bonds and brain
5 numbers linked to ideal heart health
Rating the drugs in drug ads
Postpartum anxiety is invisible, but common and treatable
The popularity of microdosing of psychedelics: What does the science say?
Pouring from an empty cup? Three ways to refill emotionally
Is pregnancy safe for everyone?
Questions & Answers: Is Strattera dangerous?
Q. What is the significance of the new warnings about suicide risk with Strattera?
A. In September 2005, the FDA directed the manufacturer of atomoxetine (Strattera), a new treatment marketed in 2002 for attention deficit hyperactivity disorder (ADHD), to warn consumers that suicidal thinking may increase in a small number of children taking the drug. Parents will be advised to alert the treating health care professional immediately about a child's worsening mood or thoughts of suicide.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!
